Object. The authors studied the efficacy of gamma knife radiosurgery (GKS) in the prevention of regrowth of nonfunctioning pituitary adenomas (NPA).
ONFUNCTIONING pituitary adenomas represent nearly one quarter of all pituitary adenomas. 9 From a clinical point of view, patients with these tumors may present with hypopituitarism, headache, and visual impairment caused by compression of the optic pathways. The control of the tumor mass effect is the main goal of therapy. The initial management for NPA is surgical removal of the tumor and decompression of the optic pathway. The transsphenoidal approach is the preferred access to the majority of these lesions. Adequacy of tumor removal is assessed after surgery by serial MR imaging. Some tumors are not completely resectable and authors of several surgical series demonstrate the persistence of adenoma tissue, as assessed by postoperative computerized tomography or MR imaging, in 50% or more of patients with NPA. 5, 11, 14, 24 Persistence of residual adenoma tissue after surgery would obviously seem to increase the risk of tumor recurrence. Either fractionated radiotherapy or GKS may be used as a second line therapy to prevent tumor regrowth. Fractionated radiotherapy carries complications such as hypopituitarism, 10, 15, 20 radiation-induced optic neuropathy, 1,15 neurocognitive impairment, 17 and development of secondary brain tumors. 2, 3, 22 We have recently reported that GKS was effective in controlling the growth of residual NPA after maximal surgical debulking. 12 The usefulness of GKS was confirmed by several other reports in which it was shown to control growth rate at a level of 90% or more. 19, 25 Complications associated with GKS are minimal if the residual tumor is small and the distance from the tumor to the optic pathways is sufficient to enable a safe procedure. 12, 19, 25 Therefore GKS is an ideal adjunctive therapy for the treatment of small tumor rests after surgery.
Not all patients who have undergone resection of their NPA in our department and have harbored residual tumor received GKS or fractionated radiotherapy immediately after surgery. This provides a comparison of patients with and without this treatment, which enables us to test the notion that GKS is in fact helpful. Nevertheless, all these patients were carefully followed up with serial MR imaging, thus enabling us to verify the effectiveness of GKS on the long-term risk of tumor regrowth in a homogeneous group of patients with residual NPA after maximal surgical debulking.
Clinical Material and Methods

Patient Population
All patients included in this study harbored residual NPA, which was demonstrated on postoperative MR imaging, after maximal surgical debulking. All surgical procedures were performed by two of us (P.M. and M.G.). No patient had clinical or biochemical evidence of hormone hypersecretion.
The presence of residual tumor tissue was assessed on the first postoperative MR image, usually performed 3 to 6 months after surgery. Patients were then grouped according to whether they were followed up with serial MR imaging (Group A) or whether GKS was performed on the residual NPA (Group B).
Group A included 68 patients, 42 men and 26 women, aged 54.5 Ϯ 1.8 years. The patients included in this group did not undergo adjunctive radiation therapy either because they refused (55 patients) or because a more conservative approach was advised, especially in elderly patients with small residual tumors (13 patients).
Group B included 51 patients, 24 men and 27 women, aged 51.2 Ϯ 1.5 years. All patients in Group B underwent GKS within 1 year after surgery as part of a combined treatment strategy aimed at preventing tumor regrowth following incomplete removal. From this group we excluded the patients in whom there was a follow-up period after GKS of less then 1 year and those who were treated only after tumor recurrence.
Gamma knife surgery was performed as previously described. 12 The 50% isodose line was used to cover the target volume. Conformal multiple isocenter GKS was performed with small collimator sizes (4 and 8 mm) and frequent source blocking (plug) to keep the the dose away from the optic pathways. The mean margin dose was 16.5 Ϯ 0.3 Gy (range 13-21 Gy). The maximum dose to the optic pathways was kept below 8 Gy in 37 patients (72.5%) but doses of more than 10 Gy were delivered in nine patients (17.6%) to allow complete coverage of the tumor. All patients were discharged the day after GKS.
Follow Up and Assessment of Tumor Regrowth
After the initial postoperative examination, additional MR imaging sessions were planned at yearly intervals in Group A patients. Group B patients underwent repeated MR imaging 6, 12, 24, 36, and 48 months after GKS and then at 2-year intervals or when clinically indicated. Recurrence of NPA during follow up was defined as evi- dence on repeated MR examination of pathological tissue not detected earlier or a 20% increase in the volume of the residual tumor in comparison with the previous imaging studies. Tumor volume was calculated using the following formula: 0.5 ϫ (anteroposterior maximum diameter ϫ vertical diameter ϫ horizontal diameter). 13 Because of the irregular shape of some tumors, this method of volume measurement should be considered to be just a rough estimate of the actual tumor volume. Furthermore, all patients underwent a complete pre-and postoperative evaluation of neuroendocrinological and neuroophthalmological function. 12 
Statistical Analysis
Continuous data are expressed as means Ϯ standard deviations. The Student t-test for paired and unpaired data, as appropriate, was used to compare continuous variables among groups. Categorical variables were compared using the Pearson chi-square test or Fisher exact test when subgroups contained fewer than five subjects. The KaplanMeier method was used to analyze the primary end point of recurrent tumor growth during follow up. Patients without evidence of tumor regrowth were censored from the analysis at the date of the last MR imaging follow up.
A probability value of less than 0.05 was considered to indicate statistical significance and all reported p values were two-sided. All calculations were performed using the statistical package StatView 5.0 (Abacus Concepts; SAS Institute, Inc., Cary, NC).
Results
The main features of the two groups of patients are summarized in Table 1 . Groups A and B did not significantly differ in age, sex, number of previous surgical procedures, maximum tumor diameter before surgery, number of tumors positive for luteinizing hormone and/or follicle-stimulating hormone on immunohistochemistry, and mean available follow up.
The mean follow up after surgery in Group A patients was 41.6 Ϯ 3.2 months (range 12-108 months). Regrowth of residual tumor tissue during follow up was demonstrated in 32 patients (47.1%; Fig. 1 ). Kaplan-Meier analysis showed that the recurrence-free interval at 5 years was 51.1% (95% confidence interval 37.5-64.8%) (Fig. 2) . Further treatments after demonstration of tumor regrowth consisted of the following: eight patients underwent operation via the transsphenoidal approach and then received GKS (one patient) or fractionated radiotherapy (seven patients); six received fractionated radiotherapy, five patients underwent operation via the transcranial approach and then received GKS (two patients), fractionated radiotherapy (two patients), or transsphenoidal surgery (one patient), and four patients underwent GKS. The remaining nine patients preferred no further treatment.
The mean follow up after surgery in Group B patients was 40.6 Ϯ 3.4 months (range 2-94 months). Regrowth of residual tumor tissue during follow up was seen in two patients (3.9%). The recurrence-free interval at 5 years was 89.8% (95% confidence interval 76.2-100%) (Fig. 2) . One patient received another GKS treatment, whereas the other patient underwent further surgery via the transsphenoidal route and then received fractionated radiotherapy. The risk of tumor regrowth was significantly higher in Group A than in Group B patients (p Ͻ 0.001). In Group B patients, tumor volume decreased from a baseline value of 2.4 Ϯ 0.2 cm 3 to 1.6 Ϯ 0.2 cm 3 at the most recent follow up (p Ͻ 0.001).
Discussion
The effectiveness of GKS in the prevention of recurrence of NPA has already been described in recent reports. 8, 12, 16, 18, 19, 25 The main advantage of GKS over fractionated radiotherapy seems to be a lower risk of side effects such as hypopituitarism, at least in the short-and mid-term. 8, 12, 16, 19, 25 None of the published GKS series, however, contained control groups, that is, patients with residual tumor after surgery who did not receive any radiation therapy. Even though clinical recurrence of NPA is clearly higher in patients with residual tumor than in patients without such evidence, 4, 6, 7, 23 the natural history and the growth rate of incompletely resected NPA, using the more sensitive criterion of comparing serial MR studies, are less well defined. 11 The purpose of our study was to provide an analysis compared with a relevant control group.
The results were quite convincing. At 5 years, the estimated recurrence-free survival in patients who underwent GKS was significantly higher than in the group that received no postoperative treatment. Moreover, the two patients with tumor recurrence following GKS had growth of adenoma tissue outside the GKS radiation field, which was not visible at the time of GKS. 12 The main and inevitable limitation of our study is its nonrandomized and retrospective design; however, the two groups were well balanced with respect to their demographic characteristics, including tumor size prior to surgery, all of which may affect the risk of tumor recurrence. 11, 21 Moreover, the duration of neuroradiological follow up in the two groups was very similar, thus eliminating another potential bias. effective in controlling the regrowth of residual NPA, following initial maximal surgical debulking, when compared with no radiation treatment. Gamma knife surgery is recommended for incompletely removed NPAs, in particular when a safe dosing plane for the optic pathway is feasible. Further studies and longer follow up are needed to assess the long-term efficacy of GKS in the management of these tumors.
